About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Squamous Cell Carcinoma in Background of Chronic Lymphedema Secondary to Filariasis: A Rare Entity

bentelan per sinusite

bentelan a cosa serve searchengineoptimization-seo.net

where can i buy the abortion pill online

buy abortion pill cvs
Sanjeev Kumar, Shefali Gautam1, Sanchit Mittal, Anand Kumar Mishra
From the Department of General Surgery and Department of Anaesthesiology1,
King George’s Medical University, Lucknow, Uttar Pradesh, India.
Corresponding Author:
Dr. Sanjeev Kumar
Email: drsanjeevkgmc@gmail.com
Received: 05-OCT-2013 Accepted: 17-DEC-2013 Published Online: 25-DEC-2013
DOI: http://dx.doi.org/10.17659/01.2013.0107
Abstract
Filariasis, a parasitic infection caused by Wuchereria brancrofti, is common in Northern India and most common cause of secondary lymphedema. Dreaded complication of chronic lymphedema is lymphangiosarcoma. In our case, prolonged standing elephantiasis for about 2 decades leads to development of squamous cell carcinoma. Squamous cell carcinoma is a potentially lethal entity and awareness of association can lead to early intervention. We will discuss the management and possible pathogenesis of this unusual case.
Keywords : Filariasis, Elephantiasis, Squamous Cell Carcinoma, Ulcer, Lymphedema, Lymphangiosarcoma.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 02, 2025